international society for pharmacoeconomics and … society for pharmacoeconomics and ......

6-8 September 2015CentroParque Event & Convention Center Located in Parque AraucanoSantiago, Chile

Co-organized by: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the ISPOR Latin America Consortium & the ISPOR Chile Regional Chapter

ConFerenCe SUPPorTing inSTiTUTionS:• Institute of Public Health, Chile • Division of Health Assessment (gETS), Ministry of Public Health, Uruguay• General Coordination for HTA, Department of Science and Technology, Ministry of Health

(DECIT-CGATS), Brazil• General Health Counsel (CSG), México • High Cost Diseases Fund (CAC), Colombia• Institute for Clinical Effectiveness and Health Policy (IECS), Argentina• Institute for Health Technology Assessment (IETS), Colombia• Interdepartmental Group for Health Economics (GRIDES), Federal University of São Paulo, Brazil• National Board of Health of the Armed Forces (D.N.S.FF.AA.), Uruguay• SaluDerecho (a World Bank initiative on prioritization, equity, and constitutional mandates

in health), Washington, DC

www.ispor.org

ISPOR 5th LatIn ameRIca cOnfeRence

Increasing Access to Health Care in Latin America: Making Better Decisions for Greater Equity

InternatIonal SocIety for pharmacoeconomIcS and outcomeS reSearch

PROgRam & ScheduLe Of eventS

cOnfeRence at-a-gLance

<< Tear out entire page for quick reference!

Please note: Session may be presented in EITHER Spanish, Portuguese, and/or English.

Sunday, 6 September

8:00-17:00 ALL DAY SHORT COURSES Separate registration required for short course attendees Introduction to Health Economics Gran Salón del Parque 1

Applied Modeling Gran Salón del Parque 2

8:00-12:00 MORNING SHORT COURSES Separate registration required for short course attendees Introduction to Modeling Las Araucarias 2 Health-Related Quality of Life / Utility Measures Las Araucarias 1

12:00-13:00 LUNCH – ATTENDEES ON THEIR OWN

13:00-17:00 AFTERNOON SHORT COURSES Separate registration required for short course attendees Extracting Cost Data for Economic Analysis in Latin America Las Araucarias 2 Meta-Analysis & Systematic Literature Review Las Araucarias 1

17:15-18:15 EDUCATIONAL SYMPOSIUM Gran Salón del Parque 2 How is Advanced Gastric Cancer Treated in Latin America? How Can We Reduce the Burden of the Disease?

18:30-19:30 EDUCATIONAL SYMPOSIUM Gran Salón del Parque 2 Sustainable Universal Health Coverage

19:45-20:45 EDUCATIONAL SYMPOSIUM Gran Salón del Parque 2 Challenges and Opportunities for Observational Research in Real World Settings

21:00-22:30 WELCOME RECEPTION Patios Austral & Ventisquero

monday, 7 September

8:30-20:00 RESEARCH POSTER PRESENTATIONS – SESSION I Loft del Parque B

8:30-9:00 WELCOME ADDRESS & OPENING REMARKS Gran Salón del Parque 1 & 2

9:00-10:30 FIRST PLENARY SESSION Gran Salón del Parque 1 & 2 Is HTA Fair? Analyzing the HTA Process in Latin America & Its Implications for Access to Health Care

10:30-11:00 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I Loft del Parque B, Patio Austral & Patio Ventisquero

11:00-12:00 ISSUE PANELS – SESSION I IP1: Dificultades para establecer umbrales de pago en América Latina, ¿Cuáles son los posibles caminos? Gran Salón del Parque 1 IP2: Desinversión en América Latina: ¿Qué experiencias, retos y propuestas pueden ser claves para una implementación exitosa? Las Araucarias 2 IP3: Planes de beneficios en salud en Latinoamérica: ¿Cuál es el estado actual y cuáles son los desafíos futuros? Gran Salón del Parque 3 IP4: ¿Podemos fortalecer la capacidad de investigación en evaluación de tecnologías sanitarias en América Latina? Las Araucarias 1

IP5: International Cooperation between Argentina, Brazil and Uruguay: How Can Cost-Effectiveness Production and Sharing Health Knowledge with Mercosur Support Decision Making? Gran Salón del Parque 2

12:00-15:00 LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I Loft del Parque B, Patio Austral & Patio Ventisquero

12:30-13:30 EDUCATIONAL SYMPOSIUM Gran Salón del Parque 2 Need, Challenges, and Solutions for Real-World Evidence (RWE): Multiple Perspectives on Evolving the Future

13:45-14:45 EDUCATIONAL SYMPOSIUM Gran Salón del Parque 2 Using Data and Analytics to Optimize Care, Benefits, and Affordability

15:00-16:00 WORKSHOPS – SESSION I W1: Changing the History of Cost-Effectiveness Decision Rules: How Will the First

Empirical Estimates of Cost-Effectiveness Threshold Impact the Decision Processes in Latin America? Gran Salón del Parque 2 W2: Examinar el impacto del uso de evaluación de tecnologías sanitarias (ETS) y precios internacionales de referencia sobre el acceso para pacientes en América Latina Gran Salón del Parque 1 W3: Generando y utilizando evidencia en el mundo real para América Latina: Estableciendo sociedades, hallando información, evaluando apropiadamente, y generando decisiones: Perspectivas locales, internacionales, publicas, y privadas Gran Salón del Parque 3 W4: Indirect Treatment Comparisons: Guidance on Technical Aspects of Conducting and Interpreting Network Meta-Analyses Las Araucarias 1 W5: Un método de elicitación de los pesos de los criterios en la toma de decisiones WITHDRAWN

16:00-16:15 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I Loft del Parque B, Patio Austral & Patio Ventisquero

16:15-17:15 RESEARCH PODIUM PRESENTATIONS – SESSION I Cancer Outcomes Research Studies Gran Salón del Parque 1 Cost-Effectiveness Studies Las Araucarias 2 Infectious Disease Studies Gran Salón del Parque 3 Medical Device & Diagnostic Research Studies Las Araucarias 1

Pricing and Health System Studies Gran Salón del Parque 2

17:30-18:30 RESEARCH PODIUM PRESENTATIONS – SESSION II Budget Impact and Cost Studies Gran Salón del Parque 1 Cardiovascular Disease & Diabetes Research Studies Las Araucarias 1 Health Technology Assessment Studies Gran Salón del Parque 3

Patient and Clinician Preferences & QALY Studies Gran Salón del Parque 2 Research On Methods Studies Las Araucarias 2

18:30-19:30 RESEARCH POSTER AUTHOR DISCUSSION HOUR – SESSION I Loft del Parque B

18:30-20:00 EXHIBITORS’ RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I Loft del Parque B, Patio Austral & Patio Ventisquero

19:30-20:30 EDUCATIONAL SYMPOSIUM Gran Salón del Parque 2 High Cost Medicines and Health Care Reform – Developing Sustainable Access to Medicines in Latin America

tueSday, 8 September

8:30-14:15 RESEARCH POSTER PRESENTATIONS – SESSION II Loft del Parque B

8:30-10:30 WELCOME, 20TH ANNIVERSARY CELEBRATION & SECOND PLENARY SESSION Gran Salón del Parque 1 & 2 Access to High Cost Drugs in Latin America: Who Goes First?

10:30-11:00 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Loft del Parque B, Patio Austral & Patio Ventisquero

11:00-12:00 ISSUE PANELS – SESSION II IP6: Multi-Criteria Decision Analysis for Rare Diseases: Is It Feasible to Be Utilized for

All Diseases? Gran Salón del Parque 2 IP7: Diferencia de las evaluaciones de dispositivos médicos y fármacos: ¿Cuáles son las implicaciones en la toma de decisiones? Gran Salón del Parque 1 IP8: Fondos especiales para el financiamiento de drogas de alto costo: ¿Cuáles son las experiencias de Latinoamérica? Gran Salón del Parque 3 IP9: Los ensayos clínicos como herramienta para mejorar la eficiencia de los sistemas sanitarios en Latinoamérica Las Araucarias 1 IP10: Value-Based Pricing for Pharmaceuticals: What Are the Implications for Latin America? Las Araucarias 2

12:00-14:30 LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Loft del Parque B, Patio Austral & Patio Ventisquero

12:15-13:15 RESEARCH POSTER AUTHOR DISCUSSION HOUR – SESSION II Loft del Parque B

13:15-14:15 ISPOR FORUMS F1: Procesos de participación para actualización de planes de beneficios Las Araucarias 2 F2: Value in Health Regional Issues (ViHRI) in Latin America: From Quality Research to Publication Success Las Araucarias 1 F3: Entendiendo las brechas para la adopción de tecnología en tres países Sudamericanos Gran Salón del Parque 3 F4: análisis de decisión multicriterio (ADM) para la evaluación de tecnologías para la salud (ETS) y reembolso en América Latina: ¿Es factible en América Latina? Si es así, ¿Cuál enfoque es mejor para la región? Gran Salón del Parque 1 F5: Health Decision Making to Support Criteria Definitions: How to Harmonize Stakeholder Rights, Needs, and Obligations? Gran Salón del Parque 2

14:30-15:30 WORKSHOPS – SESSION II W6: Availability to Pay Versus Availability to Hate: The Grand Topic of Cost-

Effectiveness in Oncology Gran Salón del Parque 2 W7: Consideraciones de equidad en la toma de decisiones en salud: ¿Qué significa y cómo se mide? Gran Salón del Parque 1 W8: Cómo gestionar los medicamentos de alto impacto financiero mediante el trabajo colaborativo de evaluaciones de tecnologías sanitarias entre los países de América Latina y el Caribe Gran Salón del Parque 3 W9: Obstáculos y buenas prácticas en el uso de evidencia de la vida real (RWE) en Argentina, Brasil y México: Desde el registro a la difusión Las Araucarias 1 W10: Impacto económico de la obesidad: Desafíos metodológicos para Latinoamérica Las Araucarias 2

15:30-15:45 BREAK & EXHIBITS Loft del Parque B, Patio Austral & Patio Ventisquero

15:45-16:45 WORKSHOPS – SESSION III W11: Multicriteria Decision Analysis: Is It the Best Approach to Inform Health Care Coverage Decisions in Latin America? Gran Salón del Parque 1 W12: Desde la evaluación de tecnologías sanitarias a las guías de práctica clínica: El “Grade Approach” Gran Salón del Parque 3 W13: Modelado de variables latentes en investigación en salud: Una aproximación al análisis de ecuaciones estructurales Las Araucarias 2 W14: Exploring Innovative Approaches to Create Real-World Evidence (RWE) in Latin America Las Araucarias 1

W15: EQ-5D: The ABC Approach to Measuring and Valuing Health in Latin America Gran Salón del Parque 2

17:00-17:30 ISPOR RESEARCH AWARDS PRESENTATIONS & CLOSING REMARKS Gran Salón del Parque 2

ISPOR 5th LatIn ameRIca cOnfeRence 6-8 September 2015 / Santiago, Chile

InvItatIOnaL gROuP meetIngS and educatIOnaL fORumSISPOR Regional Consortia and Chapters encourage the geographical development of health economics and outcomes research and the global flow of ideas and information related to health care decision making. Membership is open to all, based on geographic location. Please note that these meetings are by prior invitation only. However, ISPOR encourages your future involvement in ISPOR’s Consortia and Chapters. Please visit the ISPOR website for more information and to join.

• CONSORTIUM membership is open to all individuals in and outside of Latin America who are interested in advancing the science of health economics and outcomes research and its use in health care decisions in Latin America.

• REGIONAL CHAPTER membership is open to all who reside in the country/area the Chapter represents.

• EDUCATIONAL FORUMS are by invitation only. They provide an educational platform for different health care stakeholders (i.e. patients, decision makers) to learn and discuss important health policy issues in accordance with the ISPOR mission.

The following is a listing of the ISPOR invitational and other group meetings being held during the ISPOR 5th Latin America Conference.

Saturday, 5 September 9:00-18:00 RIPERC (Red Internacional para la Prevención de la Enfermedad Renal Crónica) Workshop *See invitation for location

18:00-20:00 ISPOR-Colombian High Cost Diseases Fund (CAC) Reception *See invitation for location

Sunday, 6 September 12:30-18:00 ISPOR HTAnetLatAm Roundtable Gran Salón del Parque 3, Level B

13:30-14:30 News Across Latin America Editorial Board El Coigue, Level B

18:00-19:00 ISPOR Latin America Consortium Education Committee El Coigue, Level B

18:00-20:00 ISPOR HTAnetLatAm Roundtable Dinner

19:15-20:45 Value in Health Regional Issues Editorial Board & Editorial Advisory Board Cerro El Plomo, Level A

19:30-20:30 ISPOR Latin America Consortium Industry Committee El Canelo, Level B

Monday, 7 September 11:00-12:00 ISPOR Mexico Chapter El Canelo, Level B

11:00-12:00 ISPOR Latin America Consortium Clinicians Committee El Coigue, Level B

12:15-13:45 ISPOR Latin America Consortium Chapter Leadership Cerro El Plomo, Level A

12:30-13:30 ISPOR Colombia Chapter Las Araucarias 1, Level B

13:45-14:45 ISPOR Brazil Chapter Las Araucarias 1, Level B

14:00-15:00 ISPOR Latin America Consortium Advisory Committee Cerro El Plomo, Level A

14:00-15:00 ISPOR Argentina Chapter El Coigue, Level B

19:00-20:30 ISPOR Latin America Consortium Executive Committee El Canelo, Level B

Tuesday, 8 September 12:15-13:15 ISPOR Latin America Consortium HTA Committee Leadership El Coigue, Level B

12:15-13:15 ISPOR Ecuador Chapter Cerro El Plomo, Level A

Wednesday, 9 September 8:00-12:00 Educational Forum: Ensuring Patient Access in Latin America: Governance, Assessment Methodologies,

and Evidence-Informed Decision Making in Health Policy. Supported by an educational grant from Roche. Marriott Hotel, Ballroom G

8:30-18:30 Advance-HTA Workshop (coordinated by the London School of Economics and Political Science-LSE) *See invitation for location

Thursday, 10 September 8:30-15:00 Advance-HTA Workshop (coordinated by the London School of Economics and Political Science-LSE)

*See invitation for location

15:30-18:30 Workshop on Economic Evaluation (coordinated by RedETSA) *See invitation for location

Please note: Invitees will receive an e-mail reminder & notification of any changes to these scheduled meetings

Tear out entire page for quick reference! >>


Key InfORmatIOnCONFERENCE OBJECTIVES

Participants will be able to:• Learn new pharmacoeconomic methodologies and outcomes research

techniques;• Improve the quality of their decision making by better utilization of

pharmacoeconomic studies; and• Learn the latest about measuring quality of life and selecting

appropriate survey instruments.

CONFERENCE LANGUAGES/INTERpRETATIONOfficial conference languages are Spanish, Portuguese, and English. Plenary Sessions will be presented with simultaneous interpretation in all 3 languages. Session languages are indicated next to the session title in the Program & Schedule of Events. Sessions with simultaneous Spanish/Portuguese/English interpretation are indicated by:

All interpretation, except for symposia, sponsored by Eli Lilly

GUIDE TO THE pROGRAM & SCHEDULE OF EVENTSFor your convenience, this Program & Schedule of Events has been printed in Spanish, Portuguese, and English. For the Spanish version, refer to pages 5-30, for the Portuguese version, refer to pages 31-56, and for the English version, refer to pages 57-82.

Issue panel, workshop, ISPOR forum, and sponsored symposia descriptions are included in the language in which they are being presented. These descriptions are listed on pages 83-106.

Podium and poster abstracts are posted on the ISPOR website in the language submitted by the authors. www.ispor.org >> ISPOR 5th Latin America Conference

REGISTRATION MATERIALSThe following tickets will be printed with your name badge:• Short Course ticket for each Short Course for which you are

registered (you MUST bring your Short Course ticket to the room to collect your materials & be admitted)

• One complimentary drink ticket to the Welcome Reception: Sunday, 6 September: 21:00-22:30

• One complimentary drink ticket to the Exhibitors’ Reception: Monday, 7 September: 18:30-20:00

PLEASE NOTE: Lanyards and Program & Schedule of Events are available for pick-up near ISPOR registration.

CONFERENCE REGISTRATION/SESSIONSSeparate registration is required for all Short Courses (Sunday, 6 September). Please see ISPOR Registration for details. A schedule of ISPOR Group Meetings and Educational Forums, which are by invitation only, is provided on page 62.

Conference registration is inclusive of symposia and the Welcome Reception on Sunday, 6 September and all sessions Monday and Tuesday, no pre-registration is required.

REGISTRATION HELp DESK HOURSISPOR Registration is located in the Foyer (Level B)• Sunday, 6 September: 7:00-18:00• Monday, 7 September: 8:00-18:00• Tuesday, 8 September: 8:00-17:30

EXHIBIT HALL HOURSExhibits will be on view in the Loft del Parque B & Patios (Level B) • Monday, 7 September: 8:30-20:00• Tuesday, 8 September: 8:30-15:45

INTERNET & WI-FI ACCESSInternet stations are provided in the Exhibit-Poster Hall, the Loft del Parque B (Level B). For the convenience of conference attendees, Wi-Fi is available on the conference room floors using the following login information:Network (RED): ISPOR User: ispor15 Password: chile2015Wi-Fi is only intended for checking of email, etc., not downloading of files. Connection speeds will vary depending on the volume of users.

Internet stations are sponsored by Pharmerit .

ABSTRACT SUBMISSION HISTORICAL INFORMATION:

During the ISPOR 5th Latin America Conference, 392 posters, 38 research podiums, 15 workshops, and 10 issue panels will be presented.

RESEARCH pODIUM & pOSTER pRESENTATION ABSTRACTS

Abstracts for all research podium and poster presentations given at the ISPOR 5th Latin America Conference will be published in Value in Health Volume 18, Issue 7. Value in Health Volume 18, Issue 7 will be available to ISPOR members and ISPOR 5th Latin America Conference registrants on-line at: www.ispor.org >> Publications >> Value in Health in October 2015.

Abstracts are also currently available for viewing at the ISPOR website, www.ispor.org >> ISPOR 5th Latin America Conference. The page number to the left of the podium or poster listing in this Program & Schedule of Events refers to the page location of the abstract in the ISPOR 5th Latin America Conference Abstracts PDF. Abstracts are listed in the language in which they were submitted.

FINANCIAL DISCLOSURE INFORMATION Research podium & poster presentation financial disclosure information will be available online in October 2015 at: www.ispor.org >> Publications >> Value in Health and in Value in Health Volume 18, Issue 7. This information can also be requested at the ISPOR Registration desk.

pRESENTATION SLIDES/pOSTERS Conference plenary session, issue panel, workshop, ISPOR forum, and symposium slides will be available at www.ispor.org after the conference, subject to speaker approval. Podium & poster presentation abstracts and released slides or poster PDFs are available at the ISPOR Scientific Presentations Database (a searchable database of almost 32,000 research papers presented at ISPOR meetings) at www.ispor.org >> Scientific Presentations or scan this QR code.

Year Research Workshop Issue Case Total Not Panel Studies Accepted (%)

2007 117 12 - - 129 7.8%

2009 256 8 5 8 277 7.2%

2011 212 14 5 4 235 4.3%

2013 400 30 26 - 456 11.2%

2015 456 29 34 - 519 10.8%


Key InfORmatIOn cOntInued

HANDOUTS• Plenary Sessions: Handouts for the plenary sessions are available in

the session room at the time of the presentations.• Research Presentations, Workshops & Issue Panels: Handouts for

research (podiums and posters), workshops, and issue panels are the sole responsibility of the presenting author(s).

• ISPOR Forums: Handouts for ISPOR forums are available in the session room at the time of the presentations.

• Educational Symposia: Handouts for symposia are the sole responsibility of the host organizations.

• All Remaining Handouts will be made available at the handout table near ISPOR Registration.

Presentations are available electronically, subject to speaker approval. The Released Presentations page is accessible at www.ispor.org >> ISPOR 5th Latin America Conference. In 2013, over 65% of the sessions had presentations available.

SpEAKER INFORMATIONUpload the final version of your slide presentation in the Speaker Ready Room on the same day of your session!

All speakers are encouraged to use the Speaker Ready Room to preview their slide presentation and/or upload an updated version. Presentations submitted to ISPOR Speaker’s Corner by the specified advance deadline and all presentations uploaded/updated in the Speaker Ready Room 30 minutes prior to the session will be pre-loaded to the computer in the session room. All speakers are requested to arrive at their presentation room 15 minutes prior to the session start time. ISPOR staff will be available in the session room to assist the presenter.

a speaker ready room is provided in Cerro Altar (Level A) with the following opening hours:• Sunday, 6 September: 12:00-18:00• Monday, 7 September: 8:00-18:00• Tuesday, 8 September: 8:00-16:00

RESEARCH pODIUM pRESENTATIONSOutcomes research (clinical, economic, and patient-reported), health policy research and research on methods for the following topics will be presented as 15 minute oral presentations:BI – Budget Impact and Cost StudiesCA – Cancer Outcomes ResearchCE – Cost-Effectiveness StudiesCV – Cardiovascular Disease & Diabetes Research StudiesHT – Health Technology Assessment StudiesIN – Infectious Disease StudiesMD – Medical Device & Diagnostic Research StudiesPP – Patient and Clinician Preferences & QALY StudiesPR – Pricing and Health Systems StudiesRM – Research on Methods Studies

RESEARCH pRESENTATION AWARDS Awards are given for the Best Research Podium Presentations (up to 6) and for the Best Research Poster Presentations (up to 6). All research podium presentations are considered for an

award. Research poster presentations in approximately the top 10%, based on abstract review score, are considered for a poster presentation award. These are identified with a rosette and will be judged during the conference.

ISPOR Research Awards Presentation will be presented on Tuesday, 8 September at 17:00 in the Gran Salón del Parque 2 (Level B).

ISpOR SOCIAL MEDIACommunicating by way of social media is encouraged if it falls within the embargo and communications guidelines.Be part of the live discussion!• Tweet your comments to @ISPORorg during the

conference using #ISPORSantiago• Access expert insights and share your views on conference sessions at

the ISPOR LinkedIn Discussion Group for Latin America “Public Access & Health in Latin America” or at the general ISPOR LinkedIn Discussion Group

• Network with your peers on the ISPOR Facebook page

RECORDING & pRESS INFORMATIONISPOR supports the promotion of research presented at ISPOR conferences, while safeguarding sensitive information, data, and research findings that may not yet be available to the public. Due to the sensitive nature of data and particularly preliminary, unpublished research findings, all filming and recording of scientific sessions and the poster hall is prohibited during the conference, without the express consent of ISPOR.

Portions of the ISPOR 5th Latin America Conference may be recorded by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). By participating in the discussions, conference registrants agree that ISPOR may electronically copy, video tape, or audio tape their attendance at and involvement in any program. Registration and attendance at the ISPOR 5th Latin America Conference constitutes an agreement by the registrant to ISPOR’s use and distribution (both now and in the future) of their image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. ISPOR will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR.

Conference attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual’s scientific results. Members of the press must identify themselves as such before questioning speakers and conference attendees if using the information in a professional capacity.

More detailed information on ISPOR’s Press Pass, Legal, and Embargo Policies are available on ISPOR’s News & Press page at the ISPOR website (www.ispor.org).

CONFERENCE pROGRAM DISCLAIMERPlease be advised that while the conference program is designed to provide accurate information regarding the subject matter covered, the views, opinions, and recommendations expressed are those of the authors and speakers, not the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and thus ISPOR does not guarantee the accuracy of the information disseminated. If professional advice is desired, please consult a competent professional.

ANTITRUST COMpLIANCEIt is the undeviating policy of ISPOR to comply strictly with the letter and spirit of all Federal, State, and applicable international trade regulations and antitrust laws. Any activities of ISPOR or ISPOR-related actions of its officers, Executive Committee Members, or members that violate these regulations and laws are detrimental to the interests of ISPOR and are unequivocally contrary to ISPOR policy.

QUESTIONS & INFORMATIONPlease ask ISPOR staff members for any additional information about the conference or about ISPOR. ISPOR staff can be identified by their black shirts with ISPOR logo.


Key InfORmatIOn cOntInued

RESEARCH pOSTER pRESENTATIONS

The poster hall is organized in rows (A-N) and each poster board is numbered accordingly (e.g. A1, L15). Each poster presentation has been assigned a specific numbered board location, which is shown in BLUE, next to the poster presentation title. Please note this is different than the poster code (based on the abstract’s scientific topic), which was assigned to each poster presentation upon acceptance. Poster board numbering is shown on the floor plan on pages 109 and 124 and the row locations are also shown in the table below in BLUE. Poster presentations will be on view in the Loft del Parque B (Level B). See pages 109-137 for poster presentation titles and authors, as well as the numbered board location and abstract page reference in the ISPOR 5th Latin America Conference Research Abstracts PDF, located at www.ispor.org >> ISPOR 5th Latin America Conference.

POSTER PRESENTATION SESSIONS POSTER POSTER DISPLAY AUTHOR DISCUS- PRESENTER PRESENTER LOCATION HOURS SION HOUR* SET UP TIME DISMANTLE TIME**

SESSION I: MONDAY, 7 SEPTEMBER 8:30-20:00 18:30-19:30 8:15-8:30 20:00

PRM: RESEARCH ON METHODS ROWS A-B

PCn: CanCer ROWS B-F

PCV: CARDIOVASCULAR DISORDERS ROWS F-H

PIH: INDIVIDUAL’S HEALTH ROWS I-K

PMH: MENTAL HEALTH ROWS K

PrS: RESPIRATORY-RELATED DISORDERS ROWS K-L

PSy: SYSTEMIC DISORDERS/CONDITIONS ROWS L-N

PUK: URINARY/KIDNEY DISORDERS ROWS N

SESSION II: TUESDAY, 8 SEPTEMBER 8:30-14:15 12:15-13:15 8:15-8:30 14:15

PHP: HEALTH CARE USE & POLICY STUDIES ROWS A-E

PMD: MEDICAL DEVICE/DIAGNOSTICS ROWS E-F

Pdb: DIABETES/ENDOCRINE DISORDERS ROWS F-H

Pgi: GASTROINTESTINAL DISORDERS ROWS H-I

Pin: inFeCTion ROWS I-K

PMS: MUSCULAR-SKELETAL DISORDERS ROWS L-M

Pnd: NEUROLOGICAL DISORDERS ROWS M-N

PSS: SENSORY SYSTEMS DISORDERS ROWS N

*Presenters are required to be at their posters during the Poster Author Discussion Hour. **Posters that are not removed at the scheduled dismantle time will be discarded.

The ISPOR Educational Webinar Series on Good Practices provides ISPOR members the opportunity to learn

about leading outcomes research methodologies directly from the authors of ISPOR Good Research Practices Reports.

www.ispor.org >> Education >> Educational Webinar Series


cOnfeRence ShORt cOuRSe PROgRamSUNDAy, 6 SEpTEMBER: ALL DAy SHORT COURSES (8:00-17:00)

INTRODUCTION TO HEALTH ECONOMICS (Presented in Spanish) Gran Salón del Parque 1Track: Economic Methods

Level: Introductory. This course is suitable for those with little or no experience with pharmacoeconomics.

Faculty: Diego Rosselli, MD, MEd, MHP, Associate Professor, Health Economics, Pontificia Universidad Javeriana, Bogotá, Colombia; Manuel Espinoza, MD, MSc, PhD, Professor, Department of Public Health & Coordinator, Unit of Health Technology Assessment - Center for Clinical Research, Catholic University of Chile, Santiago, Chile and Honorary Visiting Fellow, Centre for Health Economics, University of York, York, UK

Course This course is designed to teach clinicians and new researchers how to incorporate pharmacoeconomics/health economics into study design Description: and data analysis. Participants will learn how to collect and calculate the costs of different health care or health care economic evaluation

alternative treatments, determine the economic impact of clinical outcomes, and how to identify, track, and assign costs to different types of health care resources used. The development of economic protocols and data collection sheets will be discussed. Different health economics models and techniques will be demonstrated with case studies. These include: cost-minimization, cost-of-illness, cost-effectiveness, cost-benefit, and cost-utility analysis. Decision analysis, sensitivity analysis, and discounting will also be demonstrated and practiced. Participants will learn to compare and evaluate interventions such as drugs, devices and clinical services.

AppLIED MODELING (Presented in Spanish, Portuguese & English with simultaneous Spanish/Portuguese/English interpretation) Gran Salón del Parque 2

Track: Modeling Methods

Level: Advanced. This course is suitable for those who are familiar with modeling methods and/or those who have previously taken the ISPOR Short Course, “Introduction to Modeling.”

Faculty: Mark Sculpher, PhD, MSc, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Andrew Briggs, DPhil, MSc, William R Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; Pedro Saramago, PhD, MSc, Research Fellow, Centre for Health Economics, University of York, York, UK; Marta Soares, MSc, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK

Course This course is a hands-on introduction to the use of software in the creation and analysis of cost-effectiveness Description: decision models. The basics of cost-effectiveness decision making, building and analyzing a simple Markov model will be discussed. The

key elements to make the models probabilistic will be presented and implemented. All participants must bring a Windows laptop computer with Microsoft Excel® installed and running. You will be provided download and installation instructions when you pre-register for the course.

Sunday Morning Coffee BreakCoffee Sponsored by ZRx Outcomes Research

SUNDAy, 6 SEpTEMBER: MORNING SHORT COURSES (8:00-12:00)

INTRODUCTION TO MODELING (Presented in Spanish) Las Araucarias 2Track: Modeling Methods

Level: Introductory. This introductory course requires a basic familiarity with decision analysis.

Faculty: Federico Augustovski, MD, MSc, PhD, Director, Economic Evaluations and HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina; J. Jaime Caro, MDCM, FRCPC, FACP, Chief Scientist, Evidera, Lexington, MA, USA and Adjunct Professor of Medicine & Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada; Andrés Pichon-Riviere, MD, MSc, PhD, Executive Director & Director of Health Technology Assessment & Economic Evaluations Department, Institute for Clinical Effectiveness and Health Policy (IECS), Public Health Professor, University of Buenos Aires, Buenos Aires, Argentina, and Director, WHO/PAHO Collaborating Centre in HTA, Buenos Aires, Argentina; Sebastián García Martí, MD, MSc, Economic Evaluation and HTA Coordinator, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

Course This course includes a review of Markov models, discrete event models, and other modeling techniques and their appropriate applications, Description: including a review of the ISPOR Principles of Good Practice for Decision Analytic Modeling in Health Care Evaluations, as well as the recent

ISPOR-SMDM guidelines (Value in Health 2012). Using a series of related examples, the course will carefully review the practical steps involved in developing and using these kinds of models. Instructors will cover the practical steps involved in the selection and modeling of data inputs and practical aspects related to the determination of when, why and how to handle stochastic (i.e., first order Monte Carlo Simulations) and probabilistic uncertainty (i.e., second order Monte Carlo Simulations). Issues related to the selection of model input parameters and their distributions for use in probabilistic sensitivity analyses will be considered.

EspinozaRosselli

BriggsSculpher

SoaresSaramango

CaroAugustovski

MartíPichon-Riviere


cOnfeRence ShORt cOuRSe PROgRam cOntInued

SUNDAy, 6 SEpTEMBER: MORNING SHORT COURSES (8:00-12:00) CONTINUED

HEALTH-RELATED QUALITy OF LIFE / UTILITy MEASURES (Presented in Spanish) Las Araucarias 1Track: Patient-Reported Outcomes/Preference Methods

Level: Introductory/Intermediate. This course is for those with some experience with quality of life measures in health economic evaluation.

Faculty: Rafael Alfonso, MD, MSc, PhD, Director, Value Evidence Analytics, GlaxoSmithKline R&D, King of Prussia, PA, USA and Affiliate Professor, Department of Surgery, University of Washington, Seattle, WA, USA; Yajaira Bastardo, PhD, Professor & Chair of Pharmacoeconomics & Pharmacy Administration, Central University of Venezuela, School of Pharmacy, Caracas, Venezuela

Course Conceptual, methodological, and practical methods for measuring quality of life, health status and other types of health outcomes will be Description: presented. Utility measurement, a method of determining an individual’s preference for a certain outcome represented by a quantitative

score (utility), will also be reviewed. Methods for measuring preference-based outcomes like the standard gamble, time trade-off, and visual analogue scale will be demonstrated. Additionally, utility-based instruments such as the EQ-5D, HUI, QWQ and SF-36 will be briefly discussed. Utility measurement, however, is not only about mastering these techniques; it is about using them in such a way that health care decision makers can apply the results, for instance, in cost per QALY analyses. For this purpose, one needs to be aware of shortcomings of the available utility measures and potential solutions. Furthermore, one should be aware of the decision-making context and the way results are interpreted. To equip participants with expertise in the field of utility measurement, the most important issues will be discussed, such as potential insensitivity of generic instruments for particular disease-specific problems, and to what extent adaptation of generic or disease-specific quality of life instruments may offer a solution. Also the issue of “whose values count: patient values or values from the general public?” will be discussed. Finally, we turn to interpretation in the context of resource allocation.

SUNDAy, 6 SEpTEMBER: AFTERNOON SHORT COURSES (13:00-17:00)

EXTRACTING COST DATA FOR ECONOMIC ANALySIS IN LATIN AMERICA (Presented in Spanish) Las Araucarias 2Track: Economic Methods

Level: Intermediate. This course is designed for those with some experience with pharmacoeconomic analysis.

Faculty: Ximena Burbano-Levy, MD, MPH, Founder & CEO, Zilonis Health Economics Consulting Group, Miami, FL, USA

Course This course will focus on practical aspects of cost development for pharmacoeconomic studies. The objective is to help the Description: participant bridge the gap between understanding pharmacoeconomic theory and the practice of developing cost estimates.

Factors to consider when costing pharmacoeconomic analyses, such as perspective, data sources, data classification systems, developing resource use profiles, obtaining unit costs, and making cost adjustments will be presented. Examples of issues encountered when identifying and extracting cost data will be discussed.

META-ANALySIS & SySTEMATIC LITERATURE REVIEW (Presented in Spanish) Las Araucarias 1Track: Outcomes Research Methods

Level: Intermediate. This course is designed for those with some experience with pharmacoeconomic analysis/outcomes research methods.

Faculty: Agustín Ciapponi, MD, Coordinator, Argentine Cochrane Centre, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

Course Systematic literature review and meta-analytic methods used to assess the quality of evidence for health care interventions will be Description: discussed. Statistical approaches to pooling results from several studies and application of meta-analysis in pharmacoeconomic studies and

health care decision making will be presented.

BastardoAlfonso

Burbano-Levy

Ciapponi

8 of ISPOR’s Distance Learning Program (DLP) modules have been translated into Spanish and 5 have been translated

into Portuguese! 4 additional modules are soon to be made available in Spanish and 4 others in Portuguese!

www.ispor.org >> Education >> Distance Learning FREEACCESS!

Sunday, 6 September 8:00-17:00 CONFERENCE SHORT COURSES

Separate registration required for short course attendees

12:00-13:00 LUNCH – ATTENDEES ON THEIR OWN

17:15-18:15 EDUCATIONAL SyMpOSIUM Gran Salón del Parque 2(Presented in Spanish, Portuguese, and English with simultaneous Spanish/Portuguese/English interpretation)HOW IS ADVANCED GASTRIC CANCER TREATED IN LATIN AMERICA? HOW CAN WE REDUCE THE BURDEN OF THE DISEASE? Sponsored by Eli Lilly

18:30-19:30 EDUCATIONAL SyMpOSIUM Gran Salón del Parque 2(Presented in English with simultaneous Spanish and Portuguese interpretation)SUSTAINABLE UNIVERSAL HEALTH COVERAGE Sponsored by PhRMA

19:45-20:45 EDUCATIONAL SyMpOSIUM Gran Salón del Parque 2(Presented in Spanish, Portuguese & English with simultaneous Spanish/Portuguese/English interpretation)CHALLENGES AND OPPORTUNITIES FOR OBSERVATIONAL RESEARCH IN REAL WORLD SETTINGS Sponsored by Amgen

21:00-22:30 WELCOME RECEpTION Patios Austral & VentisqueroAll attendees welcome! Network with other conference attendees while enjoying music, drinks, and appetizers in the Austral and Ventisquero Patios (Level B) inside the CentroParque Event & Convention Center. Please see your registration materials for your free drink ticket! Cash bar also available. Co-sponsored by Pfizer Chile and Roche Chile

Monday, 7 September 8:30-20:00 RESEARCH pOSTER pRESENTATIONS - SESSION I Loft del Parque B

8:30-9:00 WELCOME ADDRESS & OpENING REMARKS Gran Salón del Parque 1 & 2(Presented in Spanish & English with simultaneous Spanish/Portuguese/English interpretation)WELCOME FROM PROGRAM COMMITTEE CO-CHAIRSJeanette Vega Morales, MD, MPH, PhD, Program Committee Co-Chair and Director, National Health Fund (FONASA), Santiago, ChileRony Lenz Alcayaga, MA, Program Committee Co-Chair, Professor, School of Public Health, University of Chile, and Head Consultant, Lenz Consulting, Santiago, Chile

WELCOME FROM ISPOR PRESIDENT Daniel C. Malone, RPh, PhD, 2015-2016 ISPOR President, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

DISTINGUISHED SERVICE AWARDS PRESENTATIONDaniel C. Malone, RPh, PhD, 2015-2016 ISPOR President, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA


PROgRam & ScheduLe Of eventS

All contributed content is listed in the language in which it was submitted to ISPOR.

LenzVega

Malone

Malone


PROgRam & ScheduLe Of eventS: mOnday, 6 SePtembeR cOntInued


AWARDEES Jeanette Vega Morales, MD, MPH, PhD, ISPOR 5th Latin America Conference Program Committee Co-Chair and Director, National Health Fund (FONASA), Santiago, Chile Rony Lenz Alcayaga, MA, ISPOR 5th Latin America Conference Program Committee Co-Chair, Professor, School of Public Health, University of Chile, and Head Consultant, Lenz Consulting, Santiago, Chile

9:00-10:30 FIRST pLENARy SESSION Gran Salón del Parque 1 & 2(Presented in English with simultaneous Spanish and Portuguese interpretation)IS HTA FAIR? ANALYZING THE HTA PROCESS IN LATIN AMERICA & ITS IMPLICATIONS FOR ACCESS TO HEALTH CARE Health technology assessment (HTA) is increasingly being used by public and private payers in Latin America to assess the effectiveness and efficiency of health care technologies for their populations – but is it fair? HTA has been implemented as a way to enable better decisions that balance varied societal and stakeholder perspectives and needs, but the question still persists of whether the decisions being made fairly represent all stakeholders. Panelists will discuss these issues from a perspective of working in an environment of equity related matters, while balancing the requirements of a rigorous scientific method to evaluate the usefulness of drugs and devices for their populations.Moderator: Louis Garrison, PhD, 2015-2016 ISPOR President-elect and Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USASpeakers: Anthony Culyer, Hon DEcon, Hon FRCP, FRSA, FMedSci, Emeritus Professor of Economics, University of York, Heslington, York, UK and Adjunct Professor, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, CanadaNorman Daniels, PhD, Mary B. Saltonstall Professor of Population Ethics and Professor of Ethics and Population Health, Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA

10:30-11:00 BREAK, EXHIBITS & RESEARCH pOSTER pRESENTATIONS VIEWING - SESSION I Loft del Parque B, Patio Austral & Patio Ventisquero

11:00-12:00 ISSUE pANELS - SESSION I

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP1: DIFICULTADES PARA ESTABLECER UMBRALES DE PAGO EN AMÉRICA LATINA, ¿CUÁLES SON LOS POSIBLES CAMINOS? (Presented in Spanish and Portuguese) Gran Salón del Parque 1 Moderator: Rodrigo Antonini Ribeiro, MD, MSc, PhD, Institute for Education and Research, Hospital Moinhos de Vento, Porto Alegre, Brazil Panelists: Federico Augustovski, MD, MSc, PhD, Director, Health Techonology Assessment and Health Economic Department, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Juan Ignacio Altuna, BEc, Asesor, Dirección de Economía de la Salud, Ministry of Health of Argentina, Buenos Aires, Argentina; Vania Cristina Canuto Santos, MSc, Substitute Director, National Commission of Incorporation of Technologies, Ministry of Health of Brazil, Brasília, Brazil

IP2: DESINVERSIÓN EN AMÉRICA LATINA: ¿QUÉ EXPERIENCIAS, RETOS Y PROPUESTAS PUEDEN SER CLAVES PARA UNA IMPLEMENTACIÓN EXITOSA? (Presented in Spanish) Las Araucarias 2 Moderator: Ion Agirrezabal, MSc, Senior Analyst, Costello Medical Consulting Ltd, Cambridge, UK Panelists: Alarico Rodríguez, PhD, Director Técnico Médico, Fondo Nacional de Recursos, Montevideo, Uruguay; María Eugenia Esandi, PhD, Professor, Universidad Nacional del Sur, Buenos Aires, Argentina; Iñaki Gutiérrez-Ibarluzea, PhD, Knowledge Manager, Basque Office for HTA, Vitoria-Gasteiz, Spain

IP3: PLANES DE BENEFICIOS EN SALUD EN LATINOAMÉRICA: ¿CUÁL ES EL ESTADO ACTUAL Y CUÁLES SON LOS DESAFÍOS FUTUROS? (Presented in Spanish) Gran Salón del Parque 3 Moderator: Manuel A. Espinoza, MD, MSc, PhD, Professor, Public Health Department, Catholic University of Chile, Santiago, Chile Panelists: Ricardo Bitran, PhD, Director, Bitran y Asociados Consultores, Santiago, Chile; Andrés Pichon-Riviere, MD, MSc, PhD, Executive Director & Director of HTA and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS) and Public Health Professor, University of Buenos Aires, Buenos Aires, Argentina

ECONOMIC OUTCOMES RESEARCH ISSUES

IP4: ¿PODEMOS FORTALECER LA CAPACIDAD DE INVESTIGACIÓN EN EVALUACIÓN DE TECNOLOGÍAS SANITARIAS EN AMÉRICA LATINA? (Presented in Spanish) Las Araucarias 1Moderator: Virginia Becerra, MSc, PhD, Access Manager, Uruguay & Paraguay, AbbVie, Montevideo, Uruguay Panelists: Rony Lenz, MA, Profesor, Escuela de Salud Pública, Unidad de Farmacoeconomía y Economía de la Salud, Universidad de Chile, Santiago, Chile; Jose Luis Segu, MSc, Consultancy Director, Oblikue Consulting, Barcelona, Spain; Rosina Hinojosa, MSc, Access Manager, Pfizer Perú, Lima, Perú

DanielsCulyer

Garrison

LenzVega




IP5: INTERNATIONAL COOPERATION BETWEEN ARGENTINA, BRAZIL AND URUGUAY: HOW CAN COST-EFFECTIVENESS PRODUCTION AND SHARING HEALTH KNOWLEDGE WITH MERCOSUR SUPPORT DECISION MAKING? (Presented in Spanish and Portuguese with simultaneous Spanish/Portuguese/English interpretation) Gran Salón del Parque 2Moderator: Telma Rodrigues Caldeira, Especialista em vigilância sanitaria, Regulação e Vigilância Sanitária, Superintendência de Regulação Sanitária e Acompanhamento de Mercados, Agência Nacional de Vigilância Sanitária - ANVISA, Brasilia, Brazil Panelists: Roberta Wichmann, MSc, PhD, Economista, Departamento de Ciencia e Tecnologia, Ministério da Saude do Brasil, Brasilia, Brazil; Verónica Laura Sanguine, Dirección Calidad de los Servicios de Salud, Ministerio de Salud Argentina, Buenos Aires, Argentina; Alejandra Nelly Croci González, BA, Tecnica, Ministry of Health of Uruguay, Montevideo, Uruguay

12:00-15:00 LUNCH, EXHIBITS & RESEARCH pOSTER pRESENTATIONS VIEWING – SESSION I Loft del Parque B, Patio Austral & Patio Ventisquero

12:30-13:30 EDUCATIONAL SyMpOSIUM Gran Salón del Parque 2(Presented in Spanish and English with simultaneous Spanish/Portuguese/English interpretation)NEED, CHALLENGES, AND SOLUTIONS FOR REAL-WORLD EVIDENCE (RWE): MULTIPLE PERSPECTIVES ON EVOLVING THE FUTURE Sponsored by IMS Health

13:45-14:45 EDUCATIONAL SyMpOSIUM Gran Salón del Parque 2(Presented in Portuguese and English with simultaneous Spanish/Portuguese/English interpretation)USING DATA AND ANALYTICS TO OPTIMIZE CARE, BENEFITS, AND AFFORDABILITY Sponsored by Optum

15:00-16:00 WORKSHOpS - SESSION I

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W1: CHANGING THE HISTORY OF COST-EFFECTIVENESS DECISION RULES: HOW WILL THE FIRST EMPIRICAL ESTIMATES OF COST-EFFECTIVENESS THRESHOLD IMPACT THE DECISION PROCESSES IN LATIN AMERICA? (Presented in English with simultaneous Spanish and Portuguese interpretation) Gran Salón del Parque 2Discussion Leaders: Manuel A. Espinoza, MD, MSc, PhD, Professor, Public Health Department, Catholic University of Chile, Santiago, Chile; Marta Soares, MSc, Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

W2: EXAMINAR EL IMPACTO DEL USO DE EVALUACIÓN DE TECNOLOGÍAS SANITARIAS (ETS) Y PRECIOS INTERNACIONALES DE REFERENCIA SOBRE EL ACCESO PARA PACIENTES EN AMÉRICA LATINA (Presented in Spanish) Gran Salón del Parque 1Discussion Leaders: Diego Guarin, MD, MPH, MA, Regional Market Access Lead, Market Access, Merck Sharp & Dohme, Bogotá, Colombia; Mónica Martín de Bustamante, AB, BE, Managing Director, CBPartners, New York, NY, USA; Rafael Alfonso, MD, PhD, Director, GSK, King of Prussia, PA, USA; J. Jaime Caro, MDCM, FRCPC, FACP, Profesor Adjunto de Medicina, Epidemiología y Bioestadística, Universidad McGill, Montreal, QC, Canadá y Jefe Científico, Evidera, Lexington, MA, EE.UU.

USE OF REAL WORLD DATA

W3: GENERANDO Y UTILIZANDO EVIDENCIA EN EL MUNDO REAL PARA AMÉRICA LATINA: ESTABLECIENDO SOCIEDADES, HALLANDO INFORMACIÓN, EVALUANDO APROPIADAMENTE, Y GENERANDO DECISIONES: PERSPECTIVAS LOCALES, INTERNACIONALES, PUBLICAS, Y PRIVADAS (Presented in Spanish) Gran Salón del Parque 3 Discussion Leaders: Nahila Justo, MPhil, MSc, MBA, Associate Director, HEOR, MAPI Group, Stockholm, Sweden; Joaquín Mould-Quevedo, PhD, MSc, MBA, GHEOR Project Lead, Global Market Access, Bayer Healthcare, Berlin, Germany; Gerardo Machnicki, MSc, PhD, Director, Real World Evidence, Janssen LATAM, Buenos Aires, Argentina; Iris Contreras-Hernández, MD, MSc, Investigadora Asociada, Hospital General de Zona 1A Venados, Instituto Mexicano del Seguro Social, México, D.F., México

CLINICAL OUTCOMES RESEARCH

W4: INDIRECT TREATMENT COMPARISONS: GUIDANCE ON TECHNICAL ASPECTS OF CONDUCTING AND INTERPRETING NETWORK META-ANALYSES (Presented in Spanish and English) Las Araucarias 1 Discussion Leaders: Agustín Ciapponi, MD, MSc, Staff Researcher, Health Techonology Assessment and Health Economic Department, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; David Thompson, PhD, Senior Vice President, Value & Outcomes Advisory, Quintiles, Cambridge, MA, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH

W5: UN MÉTODO DE ELICITACIÓN DE LOS PESOS DE LOS CRITERIOS EN LA TOMA DE DECISIONES WITHDRAWN




16:00-16:15 BREAK, EXHIBITS & RESEARCH pOSTER pRESENTATIONS VIEWING - SESSION I Loft del Parque B, Patio Austral & Patio Ventisquero

16:15-17:15 RESEARCH pODIUM pRESENTATIONS - SESSION I(Page numbers to the left refer to the abstract location in the ISPOR 5th Latin America Conference Research Abstracts PDF, available online at www.ispor.org)

CANCER OUTCOMES RESEARCH STUDIES (CA1, CA3, CA4 presented in Spanish; CA2 presented in Portuguese) Gran Salón del Parque 1Moderator: Rafael Alfonso C, MD, PhD, MSc, Director Value Evidence Analytics, R&D, GlaxoSmithKline, King of Prussia, PA and Affiliate Faculty School of Medicine, University of Washington, Seattle, WA, USA

Pg2 CA1 ASOCIACIÓN SIGNIFICATIVA ENTRE LA ENFERMEDAD VOLUMINOSA CERCANA A CRANEO Y NEUROEJE Y LA INFILTRACIÓN 16:15-16:30 SECUNDARIA A SISTEMA NERVIOSO CENTRAL EN PACIENTES CON LINFOMA DIFUSO DE CÉLULAS GRANDES B Huerta-Guzman J1, Ignacio-Ibarra G1, Talavera-Piña J1, Sierra-Ramírez J2, Contreras-Hernandez I1, 1Instituto Mexicano del Seguro Social,

México, D.F., México, 2Instituto Politecnico Nacional, México, D.F., México

Pg2 CA2 ACCESS TO THE PROCEDURE CARE OF COLORECTAL CANCER IN BRAZILIAN PUBLIC HEALTH SYSTEM: USE OF DIAGNOSIS 16:30-16:45 RESOURCES IN SÃO PAULO STATE Oliveira D1, Luque A1, Junqueira Junior SM1, Oliveira FM1, Cabra HA2, 1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson &

Johnson Medical, México, D.F., México

Pg2 CA3 PROFILE OF COLORECTAL CANCER TREATMENT WITHIN THE BRAZILIAN PUBLIC SETTING: ANALYSIS OF DATASUS AQ DATABASE16:45-17:00 Fabre Ballalai Ferraz A1, Rosim R1, Anaya P2, 1IMS Health, São Paulo, Brazil, 2IMS Health, México, D.F., México

Pg3 CA4 COSTO DE CÁNCER DE COLON AVANZADO EN LOS ESTABLECIMIENTOS HOSPITALARIOS DEL PERÚ17:00-17:15 Gutierrez-Aguado A1, Escobedo-Palza S2, Timana-Ruiz R3, Sobrevilla-Ricci A4, Mosqueira-Lovón R4, 1UNMSM, Lima, Perú, 2SPEAS, Lima, Perú, 3SOMPEGS, Lima, Perú, 4Abt Associates-HFG Peru, Lima, Perú

COST-EFFECTIVENESS STUDIES (CE1 presented in Portuguese; CE2, CE3, CE4 presented in Spanish) Las Araucarias 2Moderator: Manuel Antonio Espinoza, MD, MSc, PhD, Professor, Department of Public Health & Coordinator, HTA Unit, Center for Clinical Research, Catholic University of Chile, Santiago, Chile and Honorary Visiting Fellow, Centre for Health Economics, University of York, Heslington, York, UK

Pg3 CE1 COST-EFFECTIVENESS ANALYSIS FOR CERVICAL CANCER SCREENING USING HPV TESTS IN CHILE16:15-16:30 Franco Figueira S1, Cachoeira CV1, Souza FH1, Kano BY1, Silva M2, 1Roche Diagnostics LATAM, São Paulo, Brazil, 2Roche Diagnostics Chile,

Santiago, Chile

Pg3 CE2 EVALUACIÓN DEL COSTO-EFECTIVIDAD Y COSTO-UTILIDAD DEL USO DE RIVAROXABÁN EN PACIENTES CON FIBRILACIÓN 16:30-16:45 AURICULAR NO VALVULAR FRENTE A WARFARINA EN EL CONTEXTO ECUATORIANO Romero M, Alfonso Quiñones PA, Acero G, Marrugo R, Salutia Foundation, Bogotá, Colombia

Pg4 CE3 PROJECTED ECONOMIC IMPACT OF INCREASED USE OF BIOLOGIC TREATMENTS FOR RHEUMATOID ARTHRITIS IN ARGENTINA, 16:45-17:00 COLOMBIA, AND MEXICO OVER 10 YEARS Rojas Serrano J1, de Abreu MM2, Tundia N3, Skup M3, Sorg R4, Macaulay D4, Bao Y3, Chaves L3, Chao J3, 1National Autonomous University

of Mexico, México, D.F., México, 2Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, 3AbbVie Inc., North Chicago, IL, USA, 4Analysis Group, Inc., New York, NY, USA

Pg4 CE4 EVALUACIÓN COSTO-UTILIDAD DE DOS ALTERNATIVAS DE VACUNACIÓN PARA EL VIRUS DEL PAPILOMA HUMANO (VPH) EN LA 17:00-17:15 PREVENCIÓN DEL CANCER CERVICAL UTERINO Tejada RA, Bolaños-Díaz R, Beltrán J, Roman Y, Instituto Nacional de Salud, Lima, Perú

INFECTIOUS DISEASE STUDIES (IN1, IN2, IN4 presented in Spanish; IN3 presented in English) Gran Salón del Parque 3Moderator: Andrea Basagoitia, PhD, Chief of Studies and HTA, Public Health Institute, Santiago, Chile

Pg4 IN1 ANÁLISIS DE COSTO-UTILIDAD DE PCV13 VERSUS PPSV23 EN ADULTOS DE 65 AÑOS Y MÁS16:15-16:30 Biagini Leandro L1, Rojas Rubén R1, Fuentealba Francisca F1, Pezzani Marcela M2, 1Universidad Mayor, Santiago, Chile, 2Universidad San Sebastián, Santiago, Chile

Pg5 IN2 METHODOLOGICAL CHANGES IN BURDEN OF INFECTIOUS DISEASE ESTIMATION: THE CASE OF PNEUMOCOCCAL INFECTION IN 16:30-16:45 COLOMBIA Lasalvia P, Castañeda-Cardona C, Rosselli D, Pontificia Universidad Javeriana, Bogotá, Colombia

Pg5 IN3 ESTIMATING THE SUPPLY AND DEMAND OF BUTANTAN DENGUE VACCINE IN BRAZIL16:45-17:00 Garcia CR1, Wilson-Barthes M1, Coelho GE2, Domingues C2, Constenla DO1, 1Johns Hopkins University, Baltimore, MD, USA, 2Ministério da Saúde, Brasilia, Brazil

Pg5 IN4 ECONOMIC COSTS OF BACTERIAL MENINGITIS: A SYSTEMATIC REVIEW 17:00-17:15 Alvis-Zakzuk N1, Carrasquilla-Sotomayor M2, Alvis-Guzmán N2, Paternina-Caicedo A2, Herrera-Arrieta J3, Coronel-Rodríguez W2, Castillo- Saavedra D4, 1Instituto Nacional de Salud, Bogotá, Colombia, 2Universidad de Cartagena, Centro de Investigación y Docencia, Hospital

Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 3Universidad del Sinu, Cartagena, Colombia, 4Funinderma, Grupo de Investigación en Economía de la Salud, Bogotá, Colombia




MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES (MD1, MD2, MD4 presented in Spanish; MD3 presented in Portuguese) Las Araucarias 1Moderator: Iris Contreras, MD, MS, Chief of Coordination of Education and Research in Health, Hospital General de Zona 1A Dr. Rodolfo Antonio de Mucha Macías, Instituto Mexicano del Seguro Social, México D.F., México

Pg6 MD1 EVALUACIÓN ECONÓMICA DEL CARDIO-DESFIBRILADOR IMPLANTABLE COMPARADO CON LA TERAPIA FARMACOLÓGICA 16:15-16:30 OPTIMA PARA EL TRATAMIENTO DE LOS PACIENTES CON FALLA CARDIACA EN COLOMBIA Atehortua SC1, Castro P1, Ceballos M2, Senior JM1, Saldarriaga C1, Giraldo N1, 1Universidad de Antioquia, Medellín, Colombia, 2Instituto de

Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia

Pg6 MD2 MEDICAL DEVICES – FROM LICENSING TO COVERAGE: HIGHLIGHTS FROM ARGENTINA, BRAZIL, COLOMBIA, AND MEXICO 16:30-16:45 Rey-Ares L1, Garay U1, García-Martí S1, Gilardino R2, Cabra HA3, Pichón-Riviere A1, Augustovski F1, 1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Johnson & Johnson Medical Argentina, Buenos Aires, Argentina, 3Johnson & Johnson Medical,

México, D.F., México

Pg6 MD3 STAPLED HAEMORRHOIDOPEXY TO TREAT HEMORRHOIDS GRADE III AND IV: A SYSTEMATIC REVIEW AND META-ANALYSIS 16:45-17:00 Luque A1, Junqueira Junior SM1, Oliveira FM1, Oliveira D1, Cabra HA2, 1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson & Johnson Medical, México, D.F., México

Pg7 MD4 COST EFFECTIVENESS OF DRUG COATED BALLOON VERSUS PERCUTANEOUS TRANSLUMINAL BALLOON ANGIOPLASTY IN THE 17:00-17:15 TREATMENT OF PERIPHERAL ARTERIAL DISEASE IN LOWER LIMBS IN BRAZIL Pepe C1, Fahham L2, Follador W3, Valencia J4, Orozco JJ5, 1Grupo Resulta, São Paulo, Brazil, 2Sense Company, São Paulo, Brazil, 3Medtronic,

São Paulo, Brazil, 4Medtronic, Miami, FL, USA, 5Medtronic, Medellin, Colombia

PRICING AND HEALTH SYSTEM STUDIES (PR2 presented in Spanish; PR3 presented in Portuguese; PR4 presented in English with simultaneous Spanish/Portuguese/English interpretation) Gran Salón del Parque 2Moderator: Diana Téllez, MD, MPH, Chair, ISPOR Latin American Consortium Health Technology Producers (Industry) Committee, Bogotá, Colombia

Pg7 PR2 COMPETITION AND STRATEGIC REGULATION IN THE ARGENTINE PHARMACEUTICAL MARKET: A COMPARATIVE STUDY OF SIX 16:15-16:30 THERAPEUTIC CLASSES Maceira D, Palacios A, Center for the Study of State and Society (CEDES), Buenos Aires, Argentina

Pg8 PR3 POTENTIAL PUBLIC RESOURCE SAVINGS IN BRAZIL: THE SOMATROPIN CASE16:30-16:45 Lemos LL1, Silva MR1, Santos JB2, Costa Jd1, Gomes RM1, Nascimento RC2, Almeida AM3, Guerra Júnior AA2, 1CCATES, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, 3College of Medical

Sciences of Minas Gerais, Belo Horizonte, Brazil

Pg8 PR4 IMPACT OF MAJOR CHANGES TO THE BRAZILIAN HEALTH CARE SYSTEM UTILIZING THE HEAT MAPS PROJECT16:45-17:00 Panish JM1, Junqueira Junior SM2, Cabra HA3, Hutzul T4, Hensen M5, 1Ethicon, Somerville, NJ, USA, 2Johnson & Johnson Medical Brazil, São Paulo, Brazil, 3Johnson & Johnson Medical, México, D.F., México, 4Johnson & Johnson Medical Products, Markham, ON, Canada, 5Pharmerit

BV, Rotterdam, The Netherlands

17:30-18:30 RESEARCH pODIUM pRESENTATIONS - SESSION II(Page numbers to the left refer to the abstract location in the ISPOR 5th Latin America Conference Research Abstracts PDF, available online at www.ispor.org)

BUDGET IMPACT AND COST STUDIES (BI1 presented in Spanish; BI2, BI3, BI4 presented in English) Gran Salón del Parque 1Moderator: Pablo Anaya, MPH, HEOR/RWE Latin America Director, IMS Health, México D.F., México

Pg9 BI1 COST REDUCTION FOR A HEALTH SYSTEM THROUGH DECREASING NUMBER OF ELIGIBLE PATIENTS FOR BIOLOGICAL THERAPY 17:30-17:45 IN PATIENTS WITH RHEUMATOID ARTHRITIS USING THE TREAT TO TARGET RECOMMENDATIONS Santos-Moreno P, Saavedra-Martínez G, Bello-Gualtero J, Gómez-Mora D, Biomab, Centro de Artritis Reumatoide, Bogotá, Colombia

Pg9 BI2 TREATMENT PATTERNS AND BUDGETARY IMPACT OF CHEMOTHERAPY DRUGS IN A BRAZILIAN PRIVATE HEALTH PLAN (PHP)17:45-18:00 Nishikawa AM1, Castro AP1, Alves AF1, Medina P1, Clark LG2, 1Evidências - Kantar Health, Campinas, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil

Pg9 BI3 FINANCIAL IMPACT OF HOSPITAL EXPENDITURE IN CHRONIC DISEASES FOR SEGURO POPULAR18:00-18:15 Rodríguez-Aguilar R, Gutiérrez-Delgado C, Economic Analysis Unit, México, D.F., México

Pg10 BI4 HOSPITALIZATION COSTS OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN A PUBLIC HOSPITAL IN BRAZIL18:15-18:30 Henriques RS1, Piedade A2, Wiens A1, Baptista DR1, Pontarolo R1, 1Universidade Federal do Paraná, Curitiba, Brazil, 2Evidências - Kantar Health, Campinas, Brazil




CARDIOVASCULAR DISEASE & DIABETES RESEARCH STUDIES (CV1, CV2, CV3 presented in Spanish; CV4 presented in English) Las Araucarias 1Moderator: Giacomo Balbinotto Neto, PhD, Professor, Health Economics, Pharmacoeconomics & Health Assessment Economics, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil

Pg10 CV1 ASSOCIATION OF ADHERENCE STATUS AS MEASURED USING TWO SINGLE-ITEM PHYSICIAN-ADMINISTERED METHODS WITH 17:30-17:45 CARDIOVASCULAR RISK IN PATIENTS TAKING ANTIHYPERTENSIVE MEDICATION Rivera O1, Morales F2, Cordova P2, Fernández P2, López M2, MacDonald K3, Levengood M4, Vancayzeele S5, Aerts A5, Denhaerynck K3,

Abraham I4, Villa L2, 1Universidad de Concepción, Concepción, Chile, 2Facultad de Farmacia, Universidad de Concepción, Concepción, Chile, 3Matrix 45, Tucson, AZ, USA, 4The University of Arizona, Tucson, AZ, USA, 5N.V. Novartis Pharma S.A., Vilvoorde, Belgium

Pg10 CV2 APIXABAN IN PATIENTS WITH ATRIAL FIBRILLATION: PATIENT CHARACTERISTICS OF THE LATIN AMERICA COHORT FROM A 17:45-18:00 MULTINATIONAL CLINICAL TRIAL Avezum A1, Bahit MC2, Hermosillo JA3, Zanetti FL4, Perafan P5, Juarez-Garcia A6, Vulcano C7, Cubillos LA8, Korenblat Donato BM9, 1Dante

Pazzanese Institute of Cardiology, São Paulo, Brazil, 2INECO Neurociencias, Rosario, Argentina, 3Insto Nacional de Cardiología, México, D.F., México, 4Universidad de La Frontera, Temuco, Chile, 5Fundación Valle del Lili, Cali, Colombia, 6Bristol-Myers Squibb Company, México, D.F., México, 7Bristol-Myers Squibb, Buenos Aires, Argentina, 8Pfizer, New Jersey, NJ, USA, 9Bristol-Myers Squibb, Wallingford, CT, USA

Pg11 CV3 ARETAEUS: RETROSPECTIVE STUDY OF MEDICATION USAGE PATTERNS FOLLOWING THE DIAGNOSIS OF TYPE 2 DIABETES IN 18:00-18:15 LATIN AMERICA Gagliardino JJ1, Granell RA2, Eliaschewitz FG3, Iglay K4, Brodovicz K4, Yu S4, González CD4, Shankar R4, Heisel O5, Bloomfield S5, Keown P5,

Tunceli K6, 1Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), Buenos Aires, Argentina, 2Instituto Mexicano del Seguro Social, Guadalajara, México, 3CPClin Clinical Research Center, São Paulo, Brazil, 4Merck & Co., Inc., Kenilworth, NJ, USA, 5Syreon Corporation, Vancouver, BC, Canada, 6Merck & Co., Inc., North Wales, PA, USA

Pg11 CV4 ECONOMICS OF DIABETES MELLITUS: THEORY AND EVIDENCE FOR BRAZILIAN DATA IN 200818:15-18:30 Balbinotto G, Wiest R, Jacinto P, 1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

HEALTH TECHNOLOGY ASSESSMENT STUDIES (HT1 and HT4 presented in Spanish; HT2 presented in English) Gran Salón del Parque 3Moderator: Diego Guarin, MD, MPH, MA, Regional Market Access Lead for Latin America, Global Market Access, Merck Co, Bogotá, Colombia

Pg12 HT1 RAPID INCREASE OF HEALTH LITIGATION AS A MEANS OF MARKET ACCESS FOR INNOVATIVE MEDICINES IN COLOMBIA AND THE 17:30-17:45 POTENTIAL ROLE OF HEALTH TECHNOLOGY ASSESSMENT Leon Kershaw A, Izmirlieva M, IHS, London, UK

Pg12 HT2 FROM LAW TO REALITY: MEASURING TIME-TO-ACCESS OF CONITEC APPROVED DRUGS IN BRAZILIAN PUBLIC HEALTH CARE 17:45-18:00 SYSTEM (SUS) IN THE STATE OF PARANÁ Piedade AD1, Henriques RS2, 1Evidências - Kantar Health, Campinas, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil

Pg13 HT4 PROCESO DE INCORPORACIÓN DE FÁRMACOS A LA LISTA POSITIVA DE MEDICAMENTOS (LPM) PARA LOS PRESTADORES 18:00-18:15 INTEGRALES DE SALUD: EXPERIENCIA EN EL MINISTERIO DE SALUD PÚBLICA (MSP) DE URUGUAY Croci A, Deminco A, Villamil E, Alemán A, Pérez Galán A, Ministry of Public Health, Montevideo, Uruguay

PATIENT AND CLINICIAN PREFERENCES & QALY STUDIES (PP1 and PP3 presented in Portuguese; PP2 presented in Spanish; PP4 presented in English with simultaneous Spanish/Portuguese/English interpretation) Gran Salón del Parque 2Moderator: Lautaro Renati, MHE, Professor, Health Economics, Medicine School, FASTA University, Mar del Plata, Argentina

Pg13 PP1 BARRIERS TO PARTICIPATION IN TRIALS OF CANCER: A SURVEY ON CLINICAL RESEARCH PERCEPTION17:30-17:45 Holtz L1, Cecilio L1, Julian G2, Minowa E3, 1Oncoguia, São Paulo, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil, 3Evidências - Kantar Health, Campinas, Brazil

Pg13 PP2 AN EQ-5D-5L VALUE SET BASED ON URUGUAYAN POPULATION PREFERENCES: REPORT OF THE FIRST EXPERIENCE IN LATIN 17:45-18:00 AMERICA Augustovski F1, Rey-Ares L1, Irazola V1, Garay U1, Gianneo O2, Fernandez G2, Morales MR2, Gibbons L1, Ramos-Goñi JM3, 1Institute for

Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Fondo Nacional de Recursos, Montevideo, Uruguay, 3The EuroQol Group Foundation, Rotterdam, The Netherlands

Pg14 PP3 COST-EFFECTIVENESS ANALYSIS FOR CERVICAL CANCER SCREENING USING HPV TESTS IN BRAZIL18:00-18:15 Franco Figueira S1, Cachoeira CV1, Petry Hasegawa AC2, Kano BY1, Souza FH1, 1Roche Diagnostics LATAM, São Paulo, Brazil, 2Roche

Diagnostics Brazil, São Paulo, Brazil

Pg14 PP4 AN UNDEVELOPED PICTURE: THE AVAILABILITY OF UTILITY VALUATIONS IN LATIN AMERICA – HOW WILL THEY AFFECT QALYS?18:15-18:30 Montgomery S1, Stewart G2, Kusel J1, 1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Consulting Ltd., Cambridge, UK


PROgRam & ScheduLe Of eventS: mOnday, 6 SePtembeR cOntInued & tueSday, 8 SePtembeR


RESEARCH ON METHODS STUDIES (Presented in Spanish) Las Araucarias 2Moderator: Jorge Elgart, BEc, MSc, Unidad de Economía de la Salud, Centro de Endocrinologia Experimental y Aplicada (UNLP-CONICET), La Plata, Argentina

Pg14 RM1 STANDARDIZATION PROCESS OF RAW DATASUS AND CONSUMPTION ANALYSIS OF ONCOLOGY THERAPIES IN THE BRAZIL PUBLIC 17:30-17:45 HEALTH CARE SYSTEM: A COMPARISON BETWEEN RAW AND STANDARDIZED DATASET IN COLORECTAL AND LUNG CANCER Fabre Ballalai Ferraz A1, Rosim R1, Anaya P2, 1IMS Health, São Paulo, Brazil, 2IMS Health, México, D.F., México

Pg15 RM2 EXTRACTING AND USING DATA FROM ELECTRONIC MEDICAL RECORDS (EMR) TO MONITOR QUALITY OF CARE AND 17:45-18:00 PRESCRIPTION PATTERNS FOR DIABETES PREVENTION AND CONTROL IN OUTPATIENT CLINICS OF LOW AND MID RESOURCES

COUNTRIES: THE CASE OF COLIMA, MEXICO Hernández-Ávila JE1, Lara A2, Morales-Carmona E1, Espinoza EG2, Anaya P3, Palacio-Mejía LS1, 1Instituto Nacional de Salud Pública, Cuer-

navaca, México, 2Secretaría de Salud de Colima, Colima, México, 3IMS Health, México, D.F., México

Pg15 RM3 COMPARISON OF SOCIAL EQ-5D TIME TRADE-OFF VALUES IN CHILE 2008-2013: DO GEOGRAPHICAL DIFFERENCES REALLY MATTER?18:00-18:15 Zárate V1, Kind P2, Valenzuela P3, 1Ministerio de Salud, Santiago, Chile, 2University of Leeds, Leeds, UK, 3Datavoz, Santiago, Chile

Pg15 RM4 MODELO DE CARACTERIZACIÓN DE UNA POBLACIÓN AFILIADA A UNA ASEGURADA EN COLOMBIA, MEDIANTE UNA 18:15-18:30 METODOLOGÍA DE AGRUPACIÓN POR RIESGO Romero M1, Marrugo Figueroa RD2, Benavides M1, Alzate P1, Reinales J3, Quinche G3, Barrios E3, 1Salutia Foundation, Bogotá, Colom-

bia, 2Fundación Salutia, Bogotá, Colombia, 3Coomeva Group, Cali, Colombia

18:30-19:30 RESEARCH pOSTER AUTHOR DISCUSSION HOUR - SESSION I Loft del Parque B

18:30-20:00 EXHIBITORS’ RECEpTION & RESEARCH pOSTER pRESENTATIONS VIEWING - SESSION I Loft del Parque B, Patio Austral & Patio Ventisquero

19:30-20:30 EDUCATIONAL SyMpOSIUM Gran Salón del Parque 2(Presented in Spanish and English with simultaneous Spanish and English interpretation)HIGH COST MEDICINES AND HEALTH CARE REFORM – DEVELOPING SUSTAINABLE ACCESS TO MEDICINES IN LATIN AMERICA Sponsored by TEVA

Tuesday, 8 September 8:30-14:15 RESEARCH pOSTER pRESENTATIONS - SESSION II Loft del Parque B

8:30-9:00 WELCOME & 20TH ANNIVERSARy CELEBRATION Gran Salón del Parque 1 & 2(Presented in Portuguese and English with simultaneous Spanish/Portuguese/English interpretation)

WELCOME FROM ISPOR LATIN AMERICA CONSORTIUM EXECUTIVE COMMITTEE CHAIRStephen Doral Stefani, MD, 2014-2016 ISPOR Latin America Consortium Executive Committee Chair and Medical Auditor, Head of Oncology Unit, UNIMED, Porto Alegre, Brazil

WELCOME FROM ISPOR CEO & EXECUTIVE DIRECTORNancy Berg, CEO & Executive Director, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA

ISPOR 20TH ANNIVERSARY CELEBRATIONA presentation to commemorate ISPOR’s history and achievements.

Berg

Stefani

Vega


PROgRam & ScheduLe Of eventS: tueSday, 8 SePtembeR cOntInued


9:00-10:30 SECOND pLENARy SESSION Gran Salón del Parque 1 & 2(Presented in Spanish with simultaneous Portuguese and English interpretation)ACCESS TO HIGH COST DRUGS IN LATIN AMERICA: WHO GOES FIRST? Health systems in Latin America are currently experiencing constant pressure from patient groups, many of which are supported by the manufacturers themselves, as they seek access to high cost drugs via the prosecution of claims in the court system. The end goal of these claims is to ensure the financing of high cost medicines. In response to this trend, and given the natural complexity of pharmacological therapies, countries are now developing strategies to finance access to high cost drugs. Given the scarcity of available resources, it is necessary to prioritize their allocation. This session aims to review such activities in the region, and inquire about some of the critical aspects of prioritization, namely: Have certain health problems been favored and why? What types of drug therapies have high priority? Who makes these assignments? What criteria are used in the prioritization process? Are certain patient groups privileged and why? Are these solutions long or short term answers? In short, who comes first and who must wait for access to expensive drugs?Moderator: Rony Lenz Alcayaga, MA, Co-Chair, ISPOR 5th Latin America Conference and Professor, School of Public Health, University of Chile and Head Consultant, Lenz Consulting, Santiago, ChileSpeakers: María Luisa González Rétiz, MA, Director, National Center for Health Technology Excellence (CENETECSalud), México D.F., MéxicoLizbeth Acuña Merchán, MD, Executive Director, High Cost Diseases Fund (CAC), Bogotá, ColombiaJeanette Vega Morales, MD, MPH, PhD, Director, National Health Fund (FONASA), Santiago, Chile

10:30-11:00 BREAK, EXHIBITS & RESEARCH pOSTER pRESENTATIONS VIEWING - SESSION II Loft del Parque B, Patio Austral & Patio Ventisquero

11:00-12:00 ISSUE pANELS - SESSION II

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP6: MULTI-CRITERIA DECISION ANALYSIS FOR RARE DISEASES: IS IT FEASIBLE TO BE UTILIZED FOR ALL DISEASES? (Presented in Portuguese and English with simultaneous Spanish/Portuguese/English interpretation) Gran Salón del Parque 2 Moderator: Vladimir Zah, PhD(c) and Health Economics Consultant & Founder, ZRx Outcomes Research Inc., Belgrade, Serbia Panelists: Cristina Nunes Ferreira, MSc, MBA, HEOR & Pricing Manager, Pfizer Inc., São Paulo, Brazil; Carl Asche, PhD, MSc, Director, University of Illinois College of Medicine, Center for Outcomes Research, Peoria, IL, USA; Otavio Clark, PhD, MSc, Director, Evidências-A Kantar Health Company, Rio de Janeiro, Brazil

IP7: DIFERENCIA DE LAS EVALUACIONES DE DISPOSITIVOS MÉDICOS Y FÁRMACOS: ¿CUÁLES SON LAS IMPLICACIONES EN LA TOMA DE DECISIONES? (Presented in Spanish) Gran Salón del Parque 1 Moderator: Maria Luisa González Rétiz, MoA, Directora General, Secretaria de Salud, Centro Nacional de Excelencia Tecnologica en Salud (CENETEC), México, D.F., México Panelists: Rosa María Galindo-Suárez, MHE, Deputy General Director of Prioritization, General Health Council, Ministry of Health, México, D.F., México; John J. Orozco, MD, Healthcare Economics Analyst, Health Economics & Reimbursement, Medtronic, Medellín, Colombia; Olivo Omar Zanela, MSc, MF, Senior Manager, Health Economics & Market Access, Johnson & Johnson Medical Mexico, México, D.F., México

IP8: FONDOS ESPECIALES PARA EL FINANCIAMIENTO DE DROGAS DE ALTO COSTO: ¿CUÁLES SON LAS EXPERIENCIAS DE LATINOAMÉRICA? (Presented in Spanish) Gran Salón del Parque 3 Moderator: Nicolás Silva-Illanes Silva, MD, MPP, MPH, Researcher, University of Chile, Santiago, Chile Panelists: Alarico Rodríguez, MD, Director Técnico Médico, Fondo Nacional de Recursos para la Medicina Altamente Especializada, Montevideo, Uruguay; Rony Lenz Alcayaga, MSc, Professor, School of Public Health, University of Chile, Santiago, Chile; Lizbeth Acuña, Magister, Directora Ejecutiva, Cuenta de Alto Costo, Bogotá, Colombia

ECONOMIC OUTCOMES RESEARCH ISSUES

IP9: LOS ENSAYOS CLÍNICOS COMO HERRAMIENTA PARA MEJORAR LA EFICIENCIA DE LOS SISTEMAS SANITARIOS EN LATINOAMÉRICA (Presentado en español) Las Araucarias 1Moderador: Pedro Saramago Goncalves, MSc, PhD, Research Fellow, Centre of Health Economics, University of York, York, UK Panelistas: Manuel Antonio Espinoza, MD, MSc, PhD, Professor of Public Health, Pontifica Universidad Catolica de Chile, Santiago, Chile; Federico Augustovski, MD, MSc, PhD, Director, Departamento de Evaluaciones Económicas y de Tecnologías, Sanitarias Instituto de Efectividad Clínica y Sanitaria (IECS) y Profesor de Salud Pública, Universidad de Buenos Aires, Buenos Aires, Argentina; Belen Corbacho, MSc, Research Fellow in Health Economics, York Trials Unit, Department of Health Sciences, University of York, York, UK

Acuña

Lenz

González




IP10: VALUE-BASED PRICING FOR PHARMACEUTICALS: WHAT ARE THE IMPLICATIONS FOR LATIN AMERICA? (Presented in Spanish and English) Las Araucarias 2Moderator: Heidy Cáceres Rubio, MD, MHE, Director, Value, Access & Policy, Amgen Colombia, Bogotá, Colombia Panelists: J. Jaime Caro, MDCM, FRCPC, FACP, Profesor Adjunto de Medicina, Epidemiología y Bioestadística, Universidad McGill, Montreal, QC, Canadá y Jefe Científico, Evidera, Lexington, MA, EE.UU.; Virginia Becerra, MSc, PhD, Access Manager, Uruguay & Paraguay, AbbVie, Montevideo, Uruguay; Sean D. Sullivan, PhD, Professor & Dean, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

12:00-14:30 LUNCH, EXHIBITS & RESEARCH pOSTER pRESENTATIONS VIEWING - SESSION II Loft del Parque B, Patio Austral & Patio Ventisquero

12:15-13:15 RESEARCH pOSTER AUTHOR DISCUSSION HOUR - SESSION II Loft del Parque B

13:15-14:15 ISpOR FORUMS

F1: PROCESOS DE PARTICIPACIÓN PARA ACTUALIZACIÓN DE PLANES DE BENEFICIOS (Presented in Spanish) Las Araucarias 2Presented by the ISPOR Colombia Chapter Moderator: Diego Rosselli, MD, MEd, MSc, Associate Professor, Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogotá, Colombia Speakers: Manuel Antonio Espinoza, MD, MSc, PhD, Profesor del Departamento de Salud Pública y Coordinador, Unidad de Evaluación de Tecnologías Sanitarias, Centro de Investigación Clínica, Pontificia Universidad Católica de Chile, Santiago, Chile e Investigador Visitante Honorario, Centro para la Economía de Salud, Universidad de York, York, Reino Unido; Adriana Janeth Avila Reina, Econ, Economista Senior, Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia

F2: VALUE IN HEALTH REGIONAL ISSUES (VIHRI) IN LATIN AMERICA: FROM QUALITY RESEARCH TO PUBLICATION SUCCESS (Presented in Spanish and English) Las Araucarias 1Presented by Value in Health Regional Issues (ViHRI) Editorial Board for Latin America Moderator: Federico Augustovski, MD, MSc, PhD, Director, Economic Evaluations and HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS) and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina Speakers: J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Professor of Medicine, Epidemiology, and Biostatistics, McGill University, Montreal, QC, Canada and Chief Scientist, Evidera, Lexington, MA, USA; Victor Zarate, MD, MSc, PhD, Researcher, Department of Health Technology Assessment, Chilean Ministry of Health and Researcher, School of Medicine, University of Andes, Santiago, Chile; Marcos Bosi Ferraz, MD, MSc, PhD, Associate Professor, Department of Medicine, Division of Health Economics and Healthcare Management, Escola Paulista de Medicina - Federal University of São Paulo (UNIFESP) and Director, São Paulo Center for Health Economics (GRIDES), São Paulo, Brazil

F3: ENTENDIENDO LAS BRECHAS PARA LA ADOPCIÓN DE TECNOLOGÍA EN TRES PAÍSES SUDAMERICANOS (Presented in Spanish) Gran Salón del Parque 3 Presented by the ISPOR Argentina Regional Chapter in collaboration with the ISPOR Chile and Uruguay Chapters Moderator: Ramiro Eugenio Gilardino, MD, MSc, Profesor Adjunto, Medicina de Cuidados Críticos / Universidad de Buenos Aires y Gerente de Economía de la Salud y Acceso – LATAM Sur, Johnson & Johnson MD, Buenos Aires, Argentina Speakers: Rubén Torres, Centro de Evaluación de Technologías Sanitarias (CETSA) Universidad ISALUD, Buenos Aires, Argentina, y Director del Centro Colaborador de la OMS/OPS en ETS, Buenos Aires, Argentina; Rony Lenz Alcayaga, MA, Profesor Asistente, Escuela de Salud Pública, Universidad de Chile y Consultor Principal, Lenz Consultores, Santiago, Chile; Alarico Rodríguez, MD, Director, Técnico Médico, Fondo Nacional de Recursos, Montevideo, Uruguay

F4: ANÁLISIS DE DECISIÓN MULTICRITERIO (ADM) PARA LA EVALUACIÓN DE TECNOLOGÍAS PARA LA SALUD (ETS) Y REEMBOLSO EN AMÉRICA LATINA: ¿ES FACTIBLE EN AMÉRICA LATINA? SI ES ASÍ, ¿CUÁL ENFOQUE ES MEJOR PARA LA REGIÓN? (Presented in Spanish) Gran Salón del Parque 1Presented by the ISPOR Mexico Regional ChapterModerador: César Alberto Cruz Santiago, MD, PhD, Advisor, Medical Director Area, PEMEX (Petróleos Mexicanos), México, D.F., México Speakers: Dr. Andrés Pichon-Riviere, MD, MSc, PhD, Director Ejecutivo y Director del Departamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud, Instituto de Efectividad Clínica y Sanitaria (IECS), Profesor de Salud Pública, Universidad de Buenos Aires, Buenos Aires, Argentina, y Director del Centro Colaborador de la OMS/OPS en ETS, Buenos Aires, Argentina; Dr. Rafael Alfonso-Cristancho, MSc, PhD, Valor de Evidencia Analítica, GlaxoSmithKline R&D, King of Prussia, PA, EUA, y Profesor Afiliado, Departamento de Cirugía, Universidad de Washington, Seattle, WA, EUA; Rosa María Galindo-Suárez, MHE, Directora General Adjunta de Priorización, Consejo de Salubridad General, México, D.F., México

F5: HEALTH DECISION MAKING TO SUPPORT CRITERIA DEFINITIONS: HOW TO HARMONIZE STAKEHOLDER RIGHTS, NEEDS, AND OBLIGATIONS? (Presented in Portuguese and English) Gran Salón del Parque 2Presented by the ISPOR Brazil Regional ChapterModerator: Gabriela Tannus, MBA, MSc, Owner & Health Economics Director, Axia.Bio Consulting, Sao Paolo, BrazilSpeakers: Marcelo Fonseca, MD, MSc, Professor, Assistant Physician, Federal University of São Paulo, São Paulo, Brazil; Stephen Stefani, MD, Oncologist, Instituto do Cancer Mae de Deus, Porto Alegre, Brazil; Vania Cristina Canuto Santos, MSc, Substitute Director, National Commission of Incorporation of Technologies, Ministry of Health of Brazil, Brasília, Brazil




14:30-15:30 WORKSHOpS - SESSION II


W6: AVAILABILITY TO PAY VERSUS AVAILABILITY TO HATE: THE GRAND TOPIC OF COST-EFFECTIVENESS IN ONCOLOGY (Presented in Spanish and Portuguese with simultaneous Spanish/Portuguese/English interpretation) Gran Salón del Parque 2 Discussion Leaders: Diego Rosselli, MD, MEd, MSc, Associate Professor, Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogotá, Colombia; Stephen Stefani, MD, Oncologist, Instituto do Cancer Mae de Deus, Porto Alegre, Brazil; Diana Tellez, MD, MPH, Chair, ISPOR Latin American Consortium Health Technology Producers (Industry) Committee, Bogotá, Colombia

W7: CONSIDERACIONES DE EQUIDAD EN LA TOMA DE DECISIONES EN SALUD: ¿QUÉ SIGNIFICA Y CÓMO SE MIDE? (Presented in Spanish) Gran Salón del Parque 1Discussion Leaders: Sebastian Garcia, MD, MSc, Coordinator, Departamento Evaluación de Tecnologías Sanitarias y Evaluaciones Económicas, IECS, Buenos Aires, Argentina; Manuel A. Espinoza, MD, MSc, PhD, Professor, Public Health Department, Catholic University of Chile, Santiago, Chile; Baltica Cabieses, MSc, PhD, Senior Lecturer, Faculty of Medicine – Clinica Alemana, Universidad del Desarrollo, Santiago, Chile

W8: CÓMO GESTIONAR LOS MEDICAMENTOS DE ALTO IMPACTO FINANCIERO MEDIANTE EL TRABAJO COLABORATIVO DE EVALUACIONES DE TECNOLOGÍAS SANITARIAS ENTRE LOS PAÍSES DE AMÉRICA LATINA Y EL CARIBE (Presented in Spanish) Gran Salón del Parque 3 Discussion Leaders: Ana Lucía Muñoz Mejía, Esp., Especialista Sénior de Protección Social, Proyecto Regional sobre Priorización y Planes de Beneficios en Salud, Banco Interamericano de Desarrollo, Bogotá, Colombia; Rosa María Galindo-Suárez, MHE, Deputy General Director of Prioritization, General Health Council, México, D.F., México; Xavier Sánchez, MD, Esp., Técnico Consultor, Dirección de Inteligencia de la Salud, Ministerio de Salud Pública, Quito, Ecuador; Hernando Gaitán Duarte, MD, MSc, Profesor Titular, Instituto de Investigaciones Clínicas, Universidad Nacional de Colombia, Bogotá, Colombia


W9: OBSTÁCULOS Y BUENAS PRÁCTICAS EN EL USO DE EVIDENCIA DE LA VIDA REAL (RWE) EN ARGENTINA, BRASIL Y MÉXICO: DESDE EL REGISTRO A LA DIFUSIÓN (Presented in Spanish and Portuguese) Las Araucarias 1 Discussion Leaders: Nahila Justo, MPhil, MSc, MBA, Associate Director, HEOR, MAPI Group, Stockholm, Sweden; Gabriel E. Novick, MD, PhD, Director Médico General, Swiss Medical Group, Ciudad Autónoma de Buenos Aires, Argentina; Luis Angel Vázquez Martínez, Lic., Director General, Dirección General de Planeación y Coordinación Sectorial, Secreatía de Salud del Distrito Federal, México, D.F., México; Antonio Carlos Endrigo, MD, Medical Director, SOLLIS – Soluções Integradas à Saúde, Centro de Inovação e Tecnologia (CIETEC-USP), São Paulo, Brazil

ECONOMIC OUTCOMES RESEARCH

W10: IMPACTO ECONÓMICO DE LA OBESIDAD: DESAFÍOS METODOLÓGICOS PARA LATINOAMÉRICA (Presented in Spanish) Las Araucarias 2Discussion Leaders: Cristóbal Cuadrado, MD, MPH, Profesor Asistente, Unidad de Farmacoeconomia y Economía de la Salud, Departamento de Políticas, Sistemas y Gestión en Salud, Universidad de Chile, Santiago, Chile; Simón Barquera, MD, MS, PhD, Director, Área de Investigación en Políticas y Programas de Nutrición, Centro de Investigación en Nutrición y Salud, Instituto Nacional de Salud Pública, Cuernavaca, México; Rodrigo Martínez, MA, Social Affairs Officer, Economic Commission for Latin America and the Caribbean United Nations (ECLAC), Santiago, Chile; Oscar C. Vásquez, MS, PhD, Profesor Asistente, Departamento de Ingeniería Industrial, Universidad de Santiago de Chile, Santiago, Chile

15:30-15:45 BREAK & EXHIBITS Loft del Parque B, Patio Austral & Patio Ventisquero

15:45-16:45 WORKSHOpS - SESSION III


W11: MULTICRITERIA DECISION ANALYSIS: IS IT THE BEST APPROACH TO INFORM HEALTH CARE COVERAGE DECISIONS IN LATIN AMERICA? (Presented in Spanish and English) Gran Salón del Parque 1 Discussion Leaders: Manuel A. Espinoza, MD, MSc, PhD, Professor, Public Health Department, Catholic University of Chile, Santiago, Chile; Adriana Avila, BSc, Economista, Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia; Aurelio Mejia, MSc, Subdirector de Evaluación de Tecnologías en Salud, Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia; Mireille Goetghebeur, PhD MEng, Adjunct Professor, School of Public Health, University of Montreal, Montreal, QC, Canada

W12: DESDE LA EVALUACIÓN DE TECNOLOGÍAS SANITARIAS A LAS GUÍAS DE PRÁCTICA CLÍNICA: EL “GRADE APPROACH” (Presented in Spanish) Gran Salón del Parque 3Discussion Leaders: Ignacio Neumann, MD, MSc, PhD, Profesor Asistente, Medicina Interna, Pontificia Universidad Católica de Chile, Santiago, Chile; Francisca Rodríguez, MD, Asesora, Secretaría AUGE y de Coordinación Evidencial y Metodológica, Ministerio de Salud, Santiago, Chile





W13: MODELADO DE VARIABLES LATENTES EN INVESTIGACIÓN EN SALUD: UNA APROXIMACIÓN AL ANÁLISIS DE ECUACIONES ESTRUCTURALES (Presented in Spanish) Las Araucarias 2Discussion Leaders: Victor Pedrero, MSc, Investigador Asociado, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile; Báltica Cabieses, MSc, PhD, Professor, Facultad de Medicina- Clínica Alemana, Universidad del Desarrollo, Santiago, Chile; Marcela Oyarte, BSc, Associate Researcher, Faculty of Medicine- Clinica Alemana, Universidad del Desarrollo, Santiago, Chile; Pedro Zitko, MSc, Director, Unidad de Estudios Asistenciales, Complejo Asistencial Barros Luco, Santiago, Chile

W14: EXPLORING INNOVATIVE APPROACHES TO CREATE REAL-WORLD EVIDENCE (RWE) IN LATIN AMERICA (Presented in Spanish and English) Las Araucarias 1Discussion Leaders: Marilia Gomes, MD, Professor, Diabetes Unit, Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil; Juan Eugenio Hernández Ávila, MSc, DSc, Director del Centro de Información para Decisiones en Salud Pública, Instituto Nacional de Salud Pública, Cuernavaca, México; Claudia Rodrigues Soares, PhD, Epidemiology and Health Outcomes Director - Latin America, Epidemiology, GlaxoSmithKline, Rio de Janeiro, Brazil; Joshua Hiller, MBA, Senior Principal, Real-World Evidence, IMS Health, London, UK

ECONOMIC OUTCOMES RESEARCH

W15: EQ-5D: THE ABC APPROACH TO MEASURING AND VALUING HEALTH IN LATIN AMERICA (Presented in Spanish, Portuguese & English with simultaneous Spanish/Portuguese/English interpretation) Gran Salón del Parque 2Discussion Leaders: Paul Kind, Professor, Academic Unit of Health Economics, University of Leeds, Leeds, UK; Victor Zarate, MD, Investigator, DIPLAS, Ministerio de Salud, Santiago, Chile; Federico Augustovski, MD, MSc, PhD, Director, Health Techonology Assessment and Health Economic Department, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Kenya Noronha, PhD, Professor, Cedeplar-FACE-UFMG, Belo Horizonte, Brazil

17:00-17:30 ISpOR RESEARCH AWARDS pRESENTATIONS & CLOSING REMARKS Gran Salón del Parque 2(Presented in Spanish and Portuguese with simultaneous Spanish/Portuguese/English interpretation)

WELCOMEManuel Antonio Espinoza, MD, MSc, PhD, Professor, Department of Public Health & Coordinator, HTA Unit, Center for Clinical Research, Catholic University of Chile, Santiago, Chile and Honorary Visiting Fellow, Centre for Health Economics, University of York, York, UK

ISPOR RESEARCH AWARDS PRESENTATIONPresented by: Diego Rosselli, MD, MEd, MHP, Associate Professor, Health Economics, Javeriana Papal University, Bogotá, ColombiaFederico Augustovski, MD, MSc, PhD, Director, Economic Evaluations and HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS) and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina

ANNOUNCEMENT OF ISPOR 6TH LATIN AMERICA CONFERENCEStephen Doral Stefani, MD, 2014-2016 ISPOR Latin America Consortium Executive Committee Chair and Medical Auditor, Head of Oncology Unit, UNIMED, Porto Alegre, Brazil

CLOSING REMARKSJeanette Vega Morales, MD, MPH, PhD, Program Committee Co-Chair and Director, National Health Fund (FONASA), Santiago, ChileRony Lenz Alcayaga, MA, Program Committee Co-Chair, Professor, School of Public Health, University of Chile, and Head Consultant, Lenz Consulting, Santiago, Chile

Espinoza

AugustovskiRosselli

Stefani

LenzVega


ReSeaRch POSteR PReSentatIOnS OveRvIeW

Más de 390 presentaciones en póster estarán en exhibición durante la reunión en el Loft del Parque B

• La sala de presentación de pósteres está organizada en filas (A-N) y cada tablero para la colocación de pósteres está numerado conforme a esta organización (ej.: A1, L15).

• Cada presentación de pósteres tiene un lugar específico en un tablero numerado junto al título de la presentación. Por favor, tenga en cuenta que esto es diferente del código del afiche (en base al tema científico del resumen) que fue asignado a cada presentación de pósteres al momento de la aceptación.

• Títulos de las presentaciones en poster y autores, así como el número de ubicación de estos y el número de página en donde se encuentra el resumen en PDF en la página web de ISPOR, están disponible en las páginas 109-137.

• Un índice de autores está disponible en Value in Health 18 (7), el cual está disponible en línea en Octubre aquí: http://www.ispor.org/valueinhealth_index.asp.

Mais de 390 apresentações de pôsteres estarão em exposição durante a reunião no Loft del Parque B

• O salão dos pôsteres está organizado em filas, (A-N) e cada quadro do pôster está numerado de forma apropriada (ex., A1, L15).

• Cada apresentação em pôster foi designada um local no quadro dos pôsteres que está numerado ao lado do título da apresentação em pôster. Note que este número é diferente do código do pôster (baseado no tópico científico do resumo), que foi designado para cada apresentação em pôster no momento de aceitação.

• Títulos das apresentações de pôsteres e autores, bem como a localização da placa numerada e o PDF com referências da página de resumo no website da ISPOR está disponível nas páginas 109-137.

• Um índice por autor está disponível no Value in Health 18 (7), que estará online no seguinte link http://www.ispor.org/valueinhealth_index.asp em outubro.

Over 390 poster presentations will be on display during the meeting in Loft del Parque B

• The poster hall is now organized in rows (A-N) and each poster board is numbered accordingly (e.g. A1, L12).

• Each poster presentation has been assigned a specific numbered board location, which is shown next to the poster presentation title. Please note this is different than the poster code (e.g. PHP1, PCV28), which was assigned to each poster presentation upon acceptance.

• Poster presentation titles and authors, as well as the numbered board location and abstract page reference to the PDF on the ISPOR website is available on pages 109-137.

• An Author index is available in Value in Health 18 (7), which is available online at http://www.ispor.org/valueinhealth_index.asp in October.

SeSSIon I: monday, 7 SeptemberPOSTER DISPLAY HOURS: 8:30-20:00AUTHOR DISCUSSION HOUR*: 18:30-19:30

PRM: RESEARCH ON METHODS ROWS A-B

PCN: CANCER ROWS B-F

PCV: CARDIOVASCULAR DISORDERS ROWS F-H

PIH: INDIVIDUAL’S HEALTH ROWS I-K

PMH: MENTAL HEALTH ROW K

PRS: RESPIRATORY-RELATED DISORDERS ROWS K-L

PSY: SYSTEMIC DISORDERS/CONDITIONS ROWS L-N

PUK: URINARY/KIDNEY DISORDERS ROW N

POSTER PRESENTATION SESSION POSTER LOCATION

SeSSIon II: tueSday, 8 SeptemberPOSTER DISPLAY HOURS: 8:30-14:15 AUTHOR DISCUSSION HOUR*: 12:15-13:15

PHP: HEALTH CARE USE & POLICY STUDIES ROWS A-E

PMD: MEDICAL DEVICE/DIAGNOSTICS ROWS E-F

PDB: DIABETES/ENDOCRINE DISORDERS ROWS F-H

PGI: GASTROINTESTINAL DISORDERS ROWS H-I

PIN: INFECTION ROWS I-K

PMS: MUSCULAR-SKELETAL DISORDERS ROWS L-M

PND: NEUROLOGICAL DISORDERS ROWS M-N

PSS: SENSORY SYSTEMS DISORDERS ROW N

POSTER PRESENTATION SESSION POSTER LOCATION

*Presenters are required to be at their posters during the Poster Author Discussion Hour.


cOnfeRence ROOm fLOOR PLan

Gran Salón del Parque

1 2 3

PatioVentisquero

PatioAustral

Loft del Parque B

Exhibits & Poster Presentations(Monday & Tuesday)

Exhibits & Breaks

Exhibits & Breaks IS

POR

Regi

stra

tion

Level A

Cerro El PlomoCerro Alta (Speaker Ready Room)

Level B

Las Araucarias

I

Las Araucarias

II

El Canelo

El Coigue

international society for pharmacoeconomics and … society for pharmacoeconomics and ......

Documents